Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients.
Kakkar
V V
VV
Thrombosis Research Institute, London, UK.
D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D011183:Postoperative Complications / Q000191:economics / Q000503:physiopathology / Q000517:prevention & control*; D011655:Pulmonary Embolism / Q000191:economics / Q000503:physiopathology / Q000517:prevention & control*; D012307:Risk Factors; D013924:Thrombophlebitis / Q000191:economics / Q000503:physiopathology / Q000517:prevention & control*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight